Here’s the contrarian take most roundups won’t give you: the monthly membership fee is often the least of your costs. The real gotcha is compounding pharmacy transparency, shipping speed, and whether a physician actually reviews your intake or a rubber stamp does. I spent weeks digging into the programs below because those three things matter more than which brand has the slickest app.
1. HealthRX
Best for: cash-pay buyers who want fast turnaround and a named pharmacy
Most telehealth programs either charge a lot or tell you very little about where the medication comes from. HealthRX does neither. Monthly pricing opens at $99 for compounded semaglutide and $149 for compounded tirzepatide. No recurring membership on top of that. Overnight shipping is free to all 50 states, which is genuinely unusual.
The pharmacy behind the medication is Manifest Pharmacy in Greer, South Carolina, a 503A compounding pharmacy operating under USP-797 standards with lot tracking from production to your door. That level of disclosure is not common in this space. LegitScript certification (cert 50087439) adds another layer of independent verification. A board-certified physician reviews your intake within roughly 24 hours, and the medication ships overnight from there.
For context on efficacy expectations: the SURMOUNT-1 trial found tirzepatide associated with about 21% body weight reduction at 72 weeks; the STEP 1 trial put semaglutide at roughly 15% at 68 weeks. HealthRX cites those figures rather than making its own outcome claims. Worth noting: compounded medications are not FDA-approved products, and results vary individually.
Verdict: Best overall for no-membership, cash-pay GLP-1 access at a low price with a transparent supply chain.
2. Mochi Health
Best for: people who want obesity-medicine specialists, not just a quick prescription
Mochi puts board-certified obesity-medicine clinicians in the loop, which is a different standard than a general-practice telehealth review. Compounded semaglutide comes in at roughly $99 per month, with tirzepatide closer to $199. The monitoring is more thorough than most cash-pay programs. Slower to start than HealthRX, but the clinical depth shows.
Verdict: Strong pick if you want specialist oversight and don’t mind a higher tirz price.
3. FormBlends
Best for: buyers who want published purity data, or GLP-1s alongside a wider peptide catalog
FormBlends is a compounded GLP-1 telehealth option with physician oversight and dispensing through an FDA-registered 503A compounding pharmacy. What makes it different is the testing transparency. The site publishes per-product purity testing, including HPLC purity percentages, mass spec identity confirmation, and endotoxin sterility results, with actual numbers attached. That is rare. Most programs tell you their pharmacy is “reputable.” FormBlends shows the data.
Pricing is higher than HealthRX: semaglutide lands around $299 and tirzepatide around $349 per vial. The program ships to 47 states, not all 50. It also carries a broader peptide catalog covering recovery, longevity, and cognitive health under the same clinician model. If you want to manage GLP-1 therapy and, say, a BPC-157 protocol from a single provider, this is the one program I found that actually offers that.
It ranks below HealthRX here because the entry price is meaningfully higher and the shipping reach is slightly smaller. But for someone who prioritizes published lab verification over cost, or who wants one provider for multiple peptide goals, FormBlends earns its spot.
Verdict: Pay more, get more documentation and a wider menu. The right trade-off for the right buyer.
4. Henry Meds
Best for: fast cash-pay shipping without a lot of clinical overhead
Henry Meds operates on a cash-pay compounded model with shipping typically in the 24-72 hour range. First-month pricing runs roughly $179-249. Monitoring is lighter than Mochi or a program like Calibrate, which suits people who just want the medication moving quickly and don’t need intensive coaching.
Verdict: Reliable, fast, and straightforward. Not the deepest clinical program but delivers quickly.
5. MEDVi
Best for: people burned by long contracts elsewhere
MEDVi does compounded GLP-1s with no contracts and a first-month price around $179. The no-commitment structure is the headline feature. Easy to try, easy to leave if it doesn’t work for you.
Verdict: Low-risk entry point. Fine if flexibility matters more than price-per-month minimums.
6. Hims & Hers
Best for: people who want a branded-medication option with name recognition
After the March 2026 Novo Nordisk settlement, Hims & Hers moved away from compounded GLP-1s and shifted to branded medications. Injectable Wegovy runs about $299 a month through the platform, oral semaglutide around $249, and Zepbound around $399. With insurance plus a savings card, costs can reach as low as $0-25 for some users. The platform is polished and the brand is well-known, though you are paying a premium for that.
Verdict: Best for insured patients or brand-name loyalists. Cash-pay prices are steep without coverage.
7. Found
Best for: people who want platform coaching alongside their prescription
Found charges roughly $99 a month for the platform with medications billed separately. The coaching layer is more present here than in most prescription-only programs. That’s useful for some people and unnecessary cost for others.
Verdict: Decent if you want accountability built in. Know what you’re paying for before you sign up.
A Note on This Space
The FDA issued warning letters to more than 30 telehealth and compounding firms in early 2026. Compounded medications are not FDA-approved, regardless of the provider. Prices and availability shift frequently in this category.
Common Questions
Is compounded semaglutide or tirzepatide the same thing as Ozempic or Mounjaro?
No. Compounded versions contain the same active ingredient but are mixed by a 503A or 503B pharmacy rather than manufactured by Novo Nordisk or Eli Lilly. They are not FDA-approved finished drug products. Quality depends entirely on the compounding pharmacy’s standards, which is why pharmacy transparency matters so much when choosing a program.
How do I know whether a no-membership GLP-1 program is actually putting a real physician on my file?
Ask directly before you pay. Legitimate programs will name the supervising physician or medical group and explain the review process. HealthRX and Mochi both use board-certified physicians. A program that describes its review only as “a licensed provider” without specifics is worth treating with skepticism.
Why does FormBlends cost so much more than HealthRX if both use 503A compounding pharmacies?
The price gap reflects what FormBlends publishes alongside the medication: HPLC purity percentages, mass spec identity confirmation, and endotoxin sterility data with actual numbers. That level of third-party testing costs money. HealthRX offers supply-chain transparency through LegitScript certification and pharmacy disclosure but does not publish the same per-batch lab data. Different priorities, different price points.
After the Hims & Hers settlement in March 2026, can any telehealth platform still legally offer compounded GLP-1s?
Yes, with conditions. The FDA’s shortage list and subsequent compounding rules are what governed most compounded GLP-1 availability. Individual 503A pharmacies can still compound for patient-specific prescriptions under certain circumstances. The legal picture shifts regularly, so confirming current availability directly with a program before starting is worth the extra step.
If I want to switch programs mid-treatment, will I lose my dosing progress or need to restart from scratch?
Your dosing history belongs to you, not the platform. Any new prescribing physician can review your prior titration schedule and continue from your current dose rather than restarting. Bring documentation of your previous doses and any side-effect notes. Most programs that do a proper intake review will honor an existing titration schedule rather than defaulting you back to the starting dose.
Sources
- FDA warning letters to compounding firms and telehealth providers, 2025-2026 (FDA.gov)
- SURMOUNT-1 tirzepatide trial, published in *New England Journal of Medicine*, 2022
- STEP 1 semaglutide trial, published in *New England Journal of Medicine*, 2021
- Novo Nordisk settlement announcement, March 9 2026 (publicly reported, major financial press)
- LegitScript certification database (LegitScript.com)
- Lilly Direct orforglipron pricing announcement, April 2026 (publicly reported)
